Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 323.33 · gapped above the open, then crossed back over prior close. High/low 326.00 at 8:45 am ET, 319.88 at 10:00 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Our top 10 customers, including governmental agencies and group purchasing organizations ("GPO"), represented approximately 66% of revenue in fiscal 2025.”
$212B relationship
basisCOR fy2025 · closed 2025-09 $321B
FILING10-K0001140859-25-000131cik 0001140859
“The 10 largest suppliers in fiscal 2025 accounted for approximately 57% of our purchases.”
$183B relationship
basisCOR fy2025 · closed 2025-09 $321B
FILING10-K0001140859-25-000131cik 0001140859
“Our two largest customers, Walgreens Boots Alliance, Inc. ("WBA") and Evernorth Health Services (formerly Express Scripts, Inc.), accounted for approximately 26% and approximately 13%, respectively, of revenue in fiscal 2024.”
$83.5B relationship
basisCOR fy2025 · closed 2025-09 $321B
FILING10-K0001140859-24-000177cik 0001140859
“In fiscal 2025, Walgreens and Boots together accounted for approximately 25% of revenue and Evernorth Health Services accounted for approximately 13% of revenue.”
$80.3B relationship
basisCOR fy2025 · closed 2025-09 $321B
FILING10-K0001140859-25-000131cik 0001140859
“In fiscal 2025, Walgreens and Boots together accounted for approximately 25% of revenue and Evernorth Health Services accounted for approximately 13% of revenue.”
$80.3B relationship
basisCOR fy2025 · closed 2025-09 $321B
FILING10-K0001140859-25-000131cik 0001140859
“Our two largest customers, Walgreens Boots Alliance, Inc. ("WBA") and Evernorth Health Services (formerly Express Scripts, Inc.), accounted for approximately 26% and approximately 13%, respectively, of revenue in fiscal 2024.”
$41.8B relationship
basisCOR fy2025 · closed 2025-09 $321B
FILING10-K0001140859-24-000177cik 0001140859
“In June 2021, we extended to 2029 (i) our distribution agreement, pursuant to which we distribute pharmaceuticals to Walgreens pharmacies, and (ii) our generics purchasing services arrangement, under which Walgreens Boots Alliance Development GmbH ("WBAD") provides a variety of services to us, including negotiating acquisition pricing with generic manufacturers on our behalf.”
FILING10-K0001140859-24-000177cik 0001140859
“We also have a distribution agreement, pursuant to which we will supply brand-name and generic pharmaceutical products to WBA's Boots UK Ltd. subsidiary through 2031.”
FILING10-K0001140859-24-000177cik 0001140859
“The U.S. Healthcare Solutions reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers.”
FILING10-K0001140859-25-000131cik 0001140859
“The U.S. Healthcare Solutions reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers.”
FILING10-K0001140859-25-000131cik 0001140859
“The U.S. Healthcare Solutions reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers.”
FILING10-K0001140859-25-000131cik 0001140859
“We have entered into a strategic collaboration agreement with Cencora to support the commercial launch of ONS-5010/LYTENAVA globally.”
FILING10-K0001104659-25-123264cik 0001649989disclosed by OTLK
“LYMPHIR, Citius Oncology has entered into distribution agreements with Cardinal Health, Cencora and McKesson Corporation.”
FILING10-K0001213900-25-125333cik 0001506251disclosed by CTXR
“As previously disclosed, we received notice of non-renewal from an oncology customer, and in June 2025, our sales contract with that customer was terminated.”
FILING10-K0001140859-25-000131cik 0001140859
Watchlist prices, news filtered to it, and its next report on your desk.
Cencora, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Wholesale-Drugs, Proprietaries & Druggists' Sundries
Cencora, Inc. has 3 disclosed suppliers and 11 disclosed customers. Each one is named in an SEC filing, either Cencora, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
COR (Cencora, Inc.) has 3 disclosed suppliers and 11 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: OTLK +3.62%, in healthcare.